Invion is an Australian life-sciences company specializing in the development of Photodynamic Therapy (PDT) for the treatment of various cancers. With a focus on transforming cancer treatments, Invion is at the forefront of global research and development of the innovative Photosoft™ technology. Holding the license and distribution rights for Photosoft™ in Australia and New Zealand, Invion is dedicated to providing novel and effective solutions for cancer patients.

Supported by the technology licensor, RMW Cho Group Limited, Invion conducts extensive research and clinical trials to advance the Photosoft™ technology. As a listed company on ASX (ASX:IVX), Invion actively pursues collaborations and partnerships to accelerate the development and commercialization of their therapies. Located in South Melbourne, VIC, Invion welcomes collaboration and engagement from stakeholders and interested parties.

For more information about their groundbreaking research and development efforts, get in touch with Invion via phone at +61 3 9692 7222 or email them at investor@inviongroup. com. Stay up-to-date with their progress by signing up for their updates.

Invion is committed to revolutionizing cancer treatment and improving patients' lives with their cutting-edge PDT technology